HEMANGIOBLASTOMA

Course overview

HEMANGIOBLASTOMAS ARE RARE, BENIGN, HIGHLY VASCULARIZED TUMORS CLASSIFIED AS WHO GRADE 1, PRIMARILY AFFECTING THE CENTRAL NERVOUS SYSTEM. THEY MOST COMMONLY OCCUR IN THE CEREBELLUM, FOLLOWED BY THE SPINAL CORD AND BRAINSTEM. HEMANGIOBLASTOMAS CAN BE SPORADIC OR ASSOCIATED WITH VON HIPPEL-LINDAU (VHL) DISEASE, A GENETIC DISORDER THAT PREDISPOSES INDIVIDUALS TO VARIOUS TUMORS. THE CLINICAL PRESENTATION OF HEMANGIOBLASTOMAS VARIES DEPENDING ON THEIR LOCATION. CEREBELLAR TUMORS OFTEN CAUSE HEADACHES, NAUSEA, VOMITING, AND SIGNS OF INCREASED INTRACRANIAL PRESSURE, WHILE BRAINSTEM TUMORS CAN LEAD TO MOTOR AND SENSORY DEFICITS, ATAXIA, AND POTENTIALLY FATAL HEMORRHAGES. SPINAL HEMANGIOBLASTOMAS MAY RESULT IN LOCALIZED PAIN, MOTOR WEAKNESS, SENSORY DISTURBANCES, AND BOWEL OR BLADDER DYSFUNCTION.MAGNETIC RESONANCE IMAGING, WHICH TYPICALLY REVEALS A CYSTIC MASS WITH AN ENHANCING MURAL NODULE, IS USED PRIMARILY TO DIAGNOSE THE CONDITION. THE PRIMARY TREATMENT IS SURGICAL RESECTION, AND THE PROGNOSIS AFTER SURGERY IS GENERALLY FAVORABLE, WITH LOW RECURRENCE RATES. THIS ACTIVITY FOR HEALTHCARE PROFESSIONALS IS DESIGNED TO ENHANCE THE LEARNER'S COMPETENCE IN RECOGNIZING HEMANGIOBLASTOMAS, PERFORMING THE RECOMMENDED EVALUATION, AND IMPLEMENTING AN APPROPRIATE INTERPROFESSIONAL MANAGEMENT APPROACH TO IMPROVE PATIENT OUTCOMES.